The FDA’s recent release of its guidance on mobile medical applications met generally widespread support among those in industry and medical practice alike. With the clarification of regulatory guidelines, industry experts predicted a surge of new mobile applications and physicians welcomed better understanding of the role of their existing mobile devices.

While the grey area of uncertainty surrounding the necessity of FDA clearance has been reduced and physicians and patients can breathe a sigh of relief knowing that there may be federal validation for new and existing mobile healthcare tools, the document will have some rarely discussed consequences. While the mobile healthcare app market free-for-all was in absolute need of regulatory and future guidance, it’s important to note the winners and losers in the departure from a completely open playing field.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access